Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Net Cash Flow (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Net Cash Flow for 6 consecutive years, with -$414714.0 as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 113.33% to -$414714.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.4 million, a 187.64% decrease, with the full-year FY2024 number at $2.4 million, up 217.51% from a year prior.
  • Net Cash Flow was -$414714.0 for Q3 2025 at Ensysce Biosciences, up from -$840916.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $7.7 million in Q2 2021 to a low of -$4.7 million in Q2 2022.
  • A 5-year average of $81060.4 and a median of -$449586.0 in 2025 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 11612.91% in 2022, then soared 231.69% in 2024.
  • Ensysce Biosciences' Net Cash Flow stood at $5.4 million in 2021, then crashed by 125.01% to -$1.4 million in 2022, then soared by 74.86% to -$340777.0 in 2023, then plummeted by 91.19% to -$651515.0 in 2024, then skyrocketed by 36.35% to -$414714.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Net Cash Flow are -$414714.0 (Q3 2025), -$840916.0 (Q2 2025), and -$449586.0 (Q1 2025).